Table 5 : Examples of studies showing prognostic use of MGMT
methylation in glioblastoma patients.


Cancer type Status Median OS
(months)
Median PFS
(months)
Reference

Glioblastoma multiforme Methylated
Unmethylated
24.7
16.2
13.3
7.8
[95]
Glioblastoma multiforme Methylated
Unmethylated
19
13
8
6
[97]

    HR  

Glioblastoma multiforme Methylated 0.61 [96]

Peters et al.Oncology Discovery  2014 2:3DOI : 10.7243/2052-6199-2-3